Angiogenic Biomarkers as Predictive Tests for Early Onset Preeclampsia: A Population-Based Study

子痫前期是妊娠最常见的严重并发症。它是由胎盘缺陷引起的，早期没有任何症状。目前，只有对母亲S进行定期产前检查，血压和尿液才能检测到。在其最广泛的形式中，子痫前期总体上影响约1/10的妊娠，1/50的妊娠受到严重影响。如果任由其发展和发展而不被发现，可能会危及母婴的生命。先兆子痫只能通过分娩来治愈，如果不得不早产，这会使一些婴儿面临风险。最近，科学家们已经发现血液中的化学物质似乎与先兆子痫的发病有关。然而，还不知道这些生物标志物的准确性有多高？他们擅长预测先兆子痫，也不知道在怀孕多早的时候可以检测到这种联系。如果生物标志物可以提供孕妇极有可能出现症状的警告，那么就可以及早给予预防性治疗。此外，如果完全没有风险的妇女能够被识别出来，那么她们就可以避免重复去医院进行血液和尿液测试。为了确定这些生物标志物的准确性，来自三个欧洲国家的孕妇的血液和尿液样本将被带到伯明翰进行检测。这些样本在怀孕期间的三个不同时间点被捐赠，让调查人员能够确定何时是检测的最佳时间。样本的结果将匿名与血压等临床信息联系起来，看看这些生物标记物是否出现在患有先兆子痫的女性身上。对测试和临床信息的统计分析将为医生和助产士提供有关先兆子痫风险的信息，如果女性这些生物标志物检测呈阳性或阴性。

Preeclampsia is the most common of the serious complications of pregnancy. It is caused by a defect in the placenta and is symptomless in the early stages. It is currently only detectable by regular antenatal checks on the mother s blood pressure and urine. In its widest forms, preeclampsia affects about 1 in 10 pregnancies overall and 1 in 50 pregnancies severely. It is potentially life-threatening to mother and baby if allowed to develop and progress undetected. Preeclampsia is curable only by delivery, which puts some babies at risk if they have to be delivered prematurely. Recently, scientists have identified chemicals in the blood that appear to be associated with the onset of preeclampsia. However, it is not known how accurate these ?biomarkers? are at predicting preeclampsia, nor how early in the pregnancy the association can be detected. If the biomarkers could provide a warning that a pregnant woman was highly likely to develop symptoms, then preventative treatment could be given early. Furthermore, if women not at all at risk could be identified, then they could be spared repeated visits to the hospital for blood and urine tests. To determine the accuracy of these biomarkers, samples of blood and urine collected from pregnant women from three European countries will be brought to Birmingham for testing. These samples have been donated at three different time points in the pregnancy, to allow the investigators to determine when the best time to test is. The results from the samples will be anonymously linked to clinical information such as blood pressure to see if the biomarkers appear in women who develop preeclampsia. Statistical analysis of the tests and clinical information will provide doctors and midwives with information about the risk of preeclampsia if a women tests positive or negative for these biomarkers.